NewAmsterdam Pharma (NASDAQ:NAMSW – Get Free Report) was the target of a significant drop in short interest during the month of January. As of January 15th, there was short interest totaling 244 shares, a drop of 50.5% from the December 31st total of 493 shares. Based on an average trading volume of 237 shares, the short-interest ratio is presently 1.0 days. Based on an average trading volume of 237 shares, the short-interest ratio is presently 1.0 days.
NewAmsterdam Pharma Stock Performance
NewAmsterdam Pharma stock traded down $0.26 during trading hours on Friday, reaching $19.61. 400 shares of the company’s stock traded hands, compared to its average volume of 667. NewAmsterdam Pharma has a fifty-two week low of $5.45 and a fifty-two week high of $29.99. The firm’s 50 day moving average is $24.26 and its 200-day moving average is $20.24.
Institutional Investors Weigh In On NewAmsterdam Pharma
An institutional investor recently raised its position in NewAmsterdam Pharma stock. Affinity Asset Advisors LLC increased its holdings in shares of NewAmsterdam Pharma (NASDAQ:NAMSW – Free Report) by 1.3% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 245,000 shares of the company’s stock after purchasing an additional 3,043 shares during the quarter. Affinity Asset Advisors LLC’s holdings in NewAmsterdam Pharma were worth $1,960,000 as of its most recent filing with the SEC.
NewAmsterdam Pharma Company Profile
NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.
The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials.
Recommended Stories
- Five stocks we like better than NewAmsterdam Pharma
- Do not delete, read immediately
- What a Former CIA Agent Knows About the Coming Collapse
- Buy This Stock at 9:30 AM on MONDAY!
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
